Loading…
← CockpitCompetitor Analysis › LNTH Lantheus Holdings IncOpen in the cockpit ↗

Lantheus Holdings IncLNTHCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of diagnostic imaging agents (radiopharmaceuticals) used in cardiac, oncology and other nuclear-medicine imaging procedures.

Momentum strong 66
Mkt cap
$6.67B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$94.0M
20-day average traded
Fwd P/E
15.5×
forward earnings
ROIC−WACC
+11.3 pp
WACC 6.5%
Hurdle
-35 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$102.00
1D+0.2%
1W+0.4%
1M+1.6%
3M+1.8%
6M+6.2%
YTD+53.3%
1Y+94.3%
ATR %0.5%
Beta0.44
52w lowhigh8.8% off high

What Lantheus does

Maker of diagnostic imaging agents (radiopharmaceuticals) used in cardiac, oncology and other nuclear-medicine imaging procedures.

Sells imaging agents by the dose to hospitals and imaging centres, mostly through radiopharmacy networks that make and deliver them within hours because the isotopes decay quickly. Pylarify, used in prostate-cancer scans, is the main growth line, and Definity, an ultrasound contrast agent, the longer-standing one. Reimbursement terms matter.

Products and services

  • Cardiovascular imaging agents (Definity)
  • Oncology imaging (Pylarify PSMA PET agent)
  • Precision diagnostics pipeline

Customers

  • Hospitals/imaging centers
  • Radiologists/nuclear medicine physicians
  • Cardiologists/oncologists

Where it sits in the supply chain

  • Healthcare
  • Radiopharmaceuticals/diagnostic imaging
  • Nuclear medicine imaging agents

What could go right

  • Pylarify PSMA PET scan volume growth
  • Pipeline expansion into radiotherapeutics

What could go wrong

  • Reimbursement/pricing pressure on imaging agents
  • Reliance on isotope supply chain

Moat: narrow (regulatory licence, IP / patents, distribution). FDA-approved radiopharmaceutical products with specialized short-shelf-life manufacturing/distribution create barriers to entry.

Headquarters: Bedford, Massachusetts, USA · Founded: 1956 · Employees: 1,193

Named competitors

Lantheus at a glance

Size Lantheus (LNTH) is a United States Health Care company (Medical Specialties) with a market value of $6.67B, the 977th largest of 3,085 United States companies the cockpit tracks. Shares closed at $102.00 on 18 Nov 2026.

Performance Over six months the shares gained 6.2%, against +27.6% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 2.4% over the last twelve months (peer median +7.3%); the operating margin is 18.6% (peer median 15.7%).

Valuation It trades at 15.5× forward earnings against a peer median of 20.9× (2nd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -35 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.3 points above its cost of capital (6.5% WACC).

Credit Lantheus has 1 bond outstanding ($575M).

Short interest Short interest is 5.6% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 2026Peer median 128LNTH 108
Six months, rebased to 100: Lantheus against the median of its 20 peers (local-currency closes).

Lantheus financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.56B$1.54B$1.53B$1.30B$935M
Revenue growth—+1%+18%+39%—
Gross profit$957M$942M$988M$848M$582M
EBITDA$382M$382M$510M$553M$119M
Net income$270M$234M$312M$327M$28.1M
Free cash flow$393M$354M$491M$259M$263M
Capital expenditure$16.4M$41.5M$79.6M$46.6M$18.3M
Total debt$624M$623M$621M$619M$586M

Quarterly statements and history in the cockpit →

Lantheus competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+20%COHTFXCTECYPSN7747688617BLCOGETI-B300832HAE68697701LIVNMMSI300677DIAMMEDGMEDSHCBRKRLNTH6-month return →1-month return →
Up and to the right = strong over both horizons. Lantheus is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%+30%15×20×25×30×COHTFXCTECYPSN7747688617BLCOGETI-B300832HAE68697701LIVN300677DIAMMEDGMEDSHCBRKRLNTHRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lantheus is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%COHTFXCTEC7747688617BLCOGETI-B300832HAE6869LIVN300677DIAGMEDBRKRLNTHGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Lantheus is the large dot.

Lantheus competitors and peer comparison

Head to head with its named competitors (LNTH vs GEHC vs NOVN.SW vs TLX.AX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Lantheus LNTH$6.67B+6%+2%19%15.5×0.4%
GE HealthCare GEHC$37.8B+30%+7%14%15.6×5.0%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Telix Pharmaceuticals TLX.AX$2.99B-2%+27%-1%34.5×n/a
Siemens Healthineers SHL.DE$53.7B+27%+1%14%18.9×9.6%

How Lantheus compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lantheus against its 20 peers (data as of 18 Nov 2026)
MeasureLNTHPeer medianRank in peer set
1-month return+1.6%+12.8%6th lowest of 21
6-month return+6.2%+27.6%4th lowest of 21
Distance from 52-week high-8.8%-6.1%7th lowest of 21
Revenue growth (TTM)+2.4%+7.3%8th lowest of 21
Operating margin18.6%15.7%9th highest of 21
Forward P/E15.5×20.9×2nd cheapest of 21
Growth the price implies (Req g, 7 yrs)0.4%11.4%2nd least demanding of 19
Growth delivered (Del g)+35.3%+9.1%2nd highest of 19
Hurdle (Req g minus delivered)-35.0 pp+2.0 ppleast demanding of 19
ROIC minus cost of capital+11.3 pp+2.9 pp4th highest of 21
EV / EBITDA17.3×13.6×7th most expensive of 18
Net debt / EBITDA-0.2×1.0×5th least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%

Lantheus bonds and credit

Lantheus has 1 bond outstanding with $575M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Lantheus's main competitors?
Named competitors: GE HealthCare (Pharmaceutical Diagnostics) (GEHC), Bracco Diagnostics (private or unlisted), Novartis (radioligand therapy) (NOVN.SW), Telix Pharmaceuticals (TLX.AX), Siemens Healthineers (SHL.DE). The cockpit's measured peer set (industry) also includes Cochlear (COH.AX), Teleflex (TFX), ConvaTec (CTEC.L), Ypsomed (YPSN.SW), Asahi Intecc (7747.T), APT Medical (688617.SS).
Is Lantheus expensive compared with its peers?
On forward p/e it trades at 15.5× against a peer median of 20.9×, 2nd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -35 pp: the price already allows for a slowdown.
How has Lantheus stock performed?
Over six months to 18 Nov 2026 the shares returned +6.2% against +27.6% for the median peer; over one year +94.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.